{'fraction_non_alphanumeric': 0.03018867924528302, 'fraction_numerical': 0.01509433962264151, 'mean_word_length': 5.7215189873417724, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
5‐drug adjuvant chemotherapy for breast cancer

A series of 41 patients at the MGH who received 5‐drug chemotherapy, cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine and prednisone, (CMF VP) as adjuvant to surgical treatment of operable breast cancer with 4 or more positive axillary nodes is compared to an analogous group of patients treated with cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) reported by Bonadonna et al.1 in an effort to assess the contribution of the treatment program to disease control.